About ABV-1601 for MDD in Cancer Patients
Product Overview
ABV-1601 leverages the same active pharmaceutical ingredient (API) and mechanism of action as ABV-1504 and ABV-1505. The Phase I/II clinical trial for treating depression in cancer patients was approved by the U.S. FDA in December 2018. The Phase I clinical study, led by Scott Irwin M.D., Ph.D. of Cedar-Sinai Medical Center, was initiated in March of 2023.
INDICATED USE
- Depression in Cancer Patients
MECHANISM OF ACTION
- Norepinephrine Transporter (NET) Inhibitor
DEVELOPMENT PARTNER
- Cedars-Sinai Medical Center
DEVELOPMENT STATUS
- A Phase 1 clinical trial at Cedars-Sinai Medical Center was initiated in March 2023
PATENT STATUS
- Patent Granted in the United States, Great Britain, Japan, Germany, France, Italy, China, and Taiwan
TOXICOLOGY
- Genotoxicity: negative
- NOAEL in rats and dogs: 3,000mg/kg/day
CLINICAL TRIAL
- Initiated in March 2023
Botanical Solutions for Cancer Patients
ABV-1601 Development Timeline
DISCLAIMER: Clinical trials may be in early stages. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of loss. Past performance is not indicative of future results.